Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
1(9%)
Results Posted
90%(9 trials)

Phase Distribution

Ph phase_1
8
73%
Ph phase_2
3
27%

Phase Distribution

8

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
8(72.7%)
Phase 2Efficacy & side effects
3(27.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

10 of 10 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(10)

Detailed Status

Completed10
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 18 (72.7%)
Phase 23 (27.3%)

Trials by Status

completed1091%
recruiting19%

Recent Activity

1 active trials
Showing 5 of 11
recruitingphase_1

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

NCT02140255
completedphase_1

Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection

NCT02591420
completedphase_1

Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults

NCT02797171
completedphase_1

Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in Infants With HIV Receiving Combination Antiretroviral Therapy

NCT03208231
completedphase_1

Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants

NCT02256631
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT02140255Phase 1

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

Recruiting
NCT02591420Phase 1

Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection

Completed
NCT02797171Phase 1

Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults

Completed
NCT03208231Phase 1

Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in Infants With HIV Receiving Combination Antiretroviral Therapy

Completed
NCT02256631Phase 1

Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants

Completed
NCT02716675Phase 2

Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men

Completed
NCT02568215Phase 2

Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women

Completed
NCT02411539Phase 1

Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)

Completed
NCT02664415Phase 2

Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection

Completed
NCT02463227Phase 1

Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption

Completed
NCT02165267Phase 1

Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11